<DOC>
	<DOCNO>NCT00660101</DOCNO>
	<brief_summary>To determine vaccine make patient 's tumor tissue stimulate immune response patient 's tumor cell . To determine safety vaccine .</brief_summary>
	<brief_title>Trial Autologous , Hapten-Modified Vaccine , OVAX , Patients With Relapsed Stage III IV Ovarian Cancer</brief_title>
	<detailed_description>To study toxicity , safety DTH response DNP-modified autologous ovarian tumor cell vaccine DTH response unmodified ovarian tumor cell patient relapse ovarian cancer : - To determine tolerability toxicity treatment regimen - To determine whether O-Vax induces DTH response autologous , DNP-modified ovarian cancer cell - To determine whether O-Vax induces DTH response autologous , unmodified ovarian cancer cell Study Population : Patients recurrent epithelial ovarian cancer whose therapeutic tumor surgery provide mass yield adequate tumor cell vaccine preparation delayed-type hypersensitivity ( DTH ) test Study Design : A Phase I/IIa double-blind , three-dose , multi-center study Investigational Product : O-Vax : DNP-modified autologous ovarian tumor cell vaccine Dosage Form : Cell suspension Route Administration : Intradermal Dosage Treatment Schedule : Prior enrollment study , one dose 5 x 106 modify one dose 5 x 106 unmodified autologous ovarian cancer cell administer , establish negative DTH response baseline . Three dose regimen use : 5 x 105 , 2.5 x 106 , 5 x 106 DNP-modified autologous ovarian tumor cell . An initial dose DNP-modified autologous ovarian tumor cells* follow cyclophosphamide weekly dos DNP-modified autologous ovarian tumor cell mixed Bacillus Calmette Guérin ( BCG ) 6 week , complete one dose DNP-modified autologous ovarian tumor cell mixed BCG 6 month booster adequate cell - count determine prior aliquoting cryopreservation Endpoints : Treatment-emergent related adverse event , serious adverse event , Grade 3 4 laboratory abnormality Other Parameters : - Delayed-type hypersensitivity skin reaction assess induction immune response DNP-modified unmodified autologous ovarian tumor cell - CA-125 level - Survival - Exploratory analysis incorporate vitro analysis lymphocyte separate patient blood sample Duration Treatment : Up 6 month Duration Subject Participation Study : Three month patient 's last vaccine Duration Follow-up : Survival information collect via phone visit quarterly basis patient begin 30 day last scheduled visit Number Subjects Required Meet Protocol Objectives : 42 evaluable subject Number Study Centers : 4-5 Number Individual Blood Draws : 13 draw nine month Volume Blood Drawn : 11 Draws 30 mL/draw ( total 360 mL ) two draw 50mL heparinized tube</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Screening Phase Stage III IV adenocarcinoma ovary Candidate surgery excise tumor Signed informed consent tumor acquisition Treatment Phase At least 18 year age Standard surgical debulking maximum extent possible Adequate amount tumor tissue obtain surgical debulking prepare series vaccine skin test material . Administration intraperitoneal chemotherapy follow surgical debulking Intraperitoneal drug consist taxane ( paclitaxel docetaxel ) Dose taxane : paclitaxel=6075 mg/m2 / weekly x 4 docetaxel = 25 mg/m2 weekly x 4 Vaccines DTH material pas lot release Minimum 2 week maximum 6 week follow last dose intraperitoneal chemotherapy Immunocompetent , determine anergy panel perform 1 week last dose intraperitoneal chemotherapy ( baseline PPD+ patient allow ) Expected survival least 6 month Karnofsky performance status ³ 80 Signed inform consent protocol participation Alkaline phosphatase &gt; 2.5 x ULN Total bilirubin &gt; 2.0 mg/dL Creatinine &gt; 2.0 mg/dL Hemoglobin &lt; 10.0 g/dL WBC &lt; 3,000 /mm3 Platelet count &lt; 100,000/mm3 Major field radiotherapy within 6 month prior participation study Brain metastasis , unless successfully treat least 6 month prior entry Prior immunotherapy ( interferon , tumor necrosis factor , cytokine [ e.g. , interleukins ] , biological response modifier , monoclonal antibody ) within 4 week prior participation study Prior splenectomy Concurrent use systemic steroid ( Note : Topical steroid therapy [ apply skin ] contraindicate participation study , provide apply either arm . Inhaled aerosol steroid contraindicate participation study . ) Concurrent use immunosuppressive drug Concurrent use antitubercular drug ( isoniazid , rifampin , streptomycin ) Other malignancy within 5 year except curatively treat nonmelanomatous skin cancer curatively treat carcinoma situ uterine cervix Concurrent autoimmune disease , e.g. , systemic lupus erythematosus , multiple sclerosis ankylose spondylitis Concurrent medical condition would preclude compliance immunologic response study treatment Concurrent serious infection serious medical condition Receipt investigational medication within 4 week prior participation study Known gentamicin sensitivity Anergic , define inability make DTH least one following : candida , mumps , tetanus , trichophyton ( base upon availability ) , PPD Vaccine lot release failure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>vaccine</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>autologous</keyword>
</DOC>